Rhythm Pharmaceuticals
RYTM
84 hedge funds and large institutions have $688M invested in Rhythm Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 15 reducing their positions, and 14 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 15
1.16% more ownership
Funds ownership: 89.65% → 90.81% (+1.2%)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
3% less funds holding
Funds holding: 87 → 84 (-3)
19% less capital invested
Capital invested by funds: $846M → $688M (-$158M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.6M |
| 2 |
DM
Deerfield Management
New York
|
+$8.41M |
| 3 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
+$3.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.33M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.89M |
| 2 |
PA
Perceptive Advisors
New York
|
-$6.06M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$4.64M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.49M |
| 5 |
TOPU
Trustees of Princeton University
Princeton,
New Jersey
|
-$1.31M |
RYTM Hedge Fund Activity: Q2 2019 in Review
84 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2019, worth a combined $688M — down 19% from $846M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RYTM and 13 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 39 added.
The largest buyer was BlackRock, adding an estimated $9.6M. The largest seller was Fidelity Investments, cutting an estimated $9.89M.
- 84 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2019, down from 87 in Q1 2019.
- Funds reported $688M of Rhythm Pharmaceuticals stock for Q2 2019, down 19% quarter-over-quarter.
- 13 funds opened new Rhythm Pharmaceuticals positions in Q2 2019 and 14 closed out, a net change of -1 holder.
- The largest Rhythm Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $9.6M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $9.89M sold.
Based on aggregated 13F filings for Q2 2019.